Search | TVST | ARVO Journals

Showing 1 – 20 of 75

SORT: Best Match Most Recent Oldest

VIEW: Basic | Expanded

ARVO Annual Meeting Abstract June 2024

A Randomized, Sham Controlled, Masked Phase II Study for Safety of Intravitreal Implantation of NT-501 Encapsulated Cell Therapy for the Treatment of Glaucoma: Adverse Events and Structural Outcomes

Alexandria Dominguez; Gala Beykin; Mariana Nunez; Zac Wennberg Smith; George A. Cioffi; Jeffrey M Liebmann; Marzhan Atakulova; Davinder S. Grover; Jennifer Rinn; Alexus Schley; Jeffrey Louis Goldberg

Invest. Ophthalmol. Vis. Sci.. 2024; 65(7):942.

ARVO Annual Meeting Abstract June 2024

Can modifiable behavioral factors be identified to increase activation in patients with glaucoma?

Alan R Morse; Lisa A Hark; Prakash Gorroochurn; Rebecca Rojas; William H Seiple; Aakriti Garg Shukla; Yujia Wang; Stefania Maruri; Desiree Henriquez; Noga Harizman; Qing Wang; Jeffrey M Liebmann; George A. Cioffi

Invest. Ophthalmol. Vis. Sci.. 2024; 65(7):4044.

ARVO Annual Meeting Abstract June 2024

Racial and ethnic differences in baseline glaucoma disease severity

Sophie Gu; Ari Leshno; Aakriti Garg Shukla; George A Cioffi; Jeffrey M Liebmann

Invest. Ophthalmol. Vis. Sci.. 2024; 65(7):2510.

ARVO Annual Meeting Abstract June 2024

OCT metrics for the macular region are more sensitive for detecting glaucomatous progression than OCT circumpapillary metrics

Iván Marin-Franch; Yujia Wang; Gustavo De Moraes; Ari Leshno; Aakriti Garg Shukla; Jeffrey M Liebmann; George A Cioffi; Donald C Hood; Emmanouil (Manos) Tsamis

Invest. Ophthalmol. Vis. Sci.. 2024; 65(7):1451.

ARVO Annual Meeting Abstract June 2024

Perimetric testing patterns focusing on the central visual field region can be more sensitive to glaucomatous progression than more peripheral patterns

Yujia Wang; Iván Marin-Franch; Carlos Gustavo De Moraes; Ari Leshno; Aakriti Garg Shukla; Jeffrey M Liebmann; George A. Cioffi; Donald Hood; Emmanouil Tsamis

Invest. Ophthalmol. Vis. Sci.. 2024; 65(7):4800.

ARVO Annual Meeting Abstract June 2024

Use of Topographical Structure–Function Agreement For Glaucoma Screening

Ari Leshno; Donald C Hood; Jeffrey M Liebmann; George A. Cioffi; Aakriti Garg Shukla; Yonatan Shalamaev; Raam Hasharoni; Zvia Burgansky-Eliash; Alon Skaat; Emmanouil (Manos) Tsamis

Invest. Ophthalmol. Vis. Sci.. 2024; 65(7):2518.

ARVO Annual Meeting Abstract June 2024

Eyes with particular patterns of retinal ganglion cell damage at baseline are more likely to show glaucomatous progression

Grace Mao; Yujia Wang; Elizabeth Ahn; Ari Leshno; Gustavo De Moraes; Aakriti Garg Shukla; George A Cioffi; Jeffrey M Liebmann; Donald C Hood; Emmanouil Tsamis

Invest. Ophthalmol. Vis. Sci.. 2024; 65(7):2517.

ARVO Annual Meeting Abstract June 2024

A combination of OCT metrics can detect glaucoma progression sooner than a VF benchmark criterion

Emmanouil (Manos) Tsamis; Yujia Wang; Ari Leshno; Carlos Gustavo De Moraes; Aakriti Garg Shukla; George A Cioffi; Jeffrey M Liebmann; Donald C Hood

Invest. Ophthalmol. Vis. Sci.. 2024; 65(7):2537.

Glaucoma January 2024

Detecting Established Glaucoma Using OCT Alone: Utilizing an OCT Reading Center in a Real-World Clinical Setting

PDF

Ari Leshno; Emmanouil Tsamis; Sitara Hirji; Gabriel A. Gomide; Noga Harizman; Carlos Gustavo De Moraes; Aakriti Garg Shukla; George A. Cioffi; Donald C. Hood; Jeffrey M. Liebmann
TAGS: diagnostic imaging, glaucoma, reading (activity), eye
Trans. Vis. Sci. Tech.. 2024; 13(1):4. https://doi.org/10.1167/tvst.13.1.4

Perspective December 2023

A Model of Progression to Help Identify Macular Damage Due to Glaucoma

PDF

Donald C. Hood; Sol La Bruna; Ari Leshno; Gabriel A. Gomide; Mi Jeung Kim; George A. Cioffi; Jeffrey M. Liebmann; Carlos Gustavo De Moraes; Emmanouil Tsamis
TAGS: glaucoma
Invest. Ophthalmol. Vis. Sci.. 2023; 64(15):8. https://doi.org/10.1167/iovs.64.15.8

Includes: Supplemental Content

ARVO Annual Meeting Abstract June 2023

An evaluation of OCT and visual field measures as endpoints of glaucoma progression

Emmanouil (Manos) Tsamis; C. Gustavo De Moraes; George A Cioffi; Jeffrey M Liebmann; Donald C Hood

Invest. Ophthalmol. Vis. Sci.. 2023; 64(8):4310.

ARVO Annual Meeting Abstract June 2023

Focal OCT defects are predictors for future glaucoma progression in the same region

Ari Leshno; Xin Xin Xing; Emmanouil (Manos) Tsamis; Gabriel Gomide; Sol La Bruna; C. Gustavo De Moraes; George A Cioffi; Sitara Hanif Hirji; Donald C Hood; Jeffrey M Liebmann

Invest. Ophthalmol. Vis. Sci.. 2023; 64(8):2023.

ARVO Annual Meeting Abstract June 2023

24-2 Visual Field Progression Rates Better Correlate with GCL than RNFL Rate of Change in Glaucoma

Xin Xin Xing; Ari Leshno; Emmanouil Tsamis; Aakriti Garg Shukla; Qing Wang; Noga Harizman; George A Cioffi; Sitara Hanif Hirji; C. Gustavo De Moraes; Jeffrey M Liebmann

Invest. Ophthalmol. Vis. Sci.. 2023; 64(8):2010.

ARVO Annual Meeting Abstract June 2023

Manhattan Vision Screening and Follow-up Study (NYC-SIGHT) Cluster-Randomized Clinical Trial: Subanalysis of Telemedicine Retinal Findings

Desiree R. Henriquez; Jason D. Horowitz; Rabia Karani; Jennifer O. Adeghate; Prakash Gorroochurn; Lisa Park; Qing Wang; Daniel Diamond; Noga Harizman; James D. Auran; Stefania C Maruri; Jeffrey M Liebmann; George A Cioffi; Tarun Sharma; Lisa A. Hark

Invest. Ophthalmol. Vis. Sci.. 2023; 64(8):4182.

Immunology and Microbiology August 2022

Topical Glaucoma Therapy Is Associated With Alterations of the Ocular Surface Microbiome

PDF

Chih-Chiun J. Chang; Karina Somohano; Christine Zemsky; Anne-Catrin Uhlemann; Jeffrey Liebmann; George A. Cioffi; Lama A. Al-Aswad; Susan V. Lynch; Bryan J. Winn
TAGS: eye, eyedrops, glaucoma, microbiome, ocular surfaces
Invest. Ophthalmol. Vis. Sci.. 2022; 63(9):32. https://doi.org/10.1167/iovs.63.9.32

Includes: Supplemental Content

ARVO Annual Meeting Abstract June 2022

Evaluation of a Deep Learning Model on a Real-World Clinical Glaucoma Dataset

Kaveri Thakoor; Ari Leshno; Sol La Bruna; Emmanouil Tsamis; Gustavo De Moraes; Paul Sajda; Noga Harizman; Jeffrey M Liebmann; George A Cioffi; Donald C Hood

Invest. Ophthalmol. Vis. Sci.. 2022; 63(7):2026 – A0467.

ARVO Annual Meeting Abstract June 2022

Manhattan Vision Screening and Follow-up Study: Epidemiologic characteristics of individuals referred to ophthalmology

Sitara Hirji; Weijie Violet Lin; Noga Harizman; Rabia Karani; Ives A. Valenzuela; David J. Doobin; Jason D Horowitz; Lisa Park; Qing Wang; Stefania Maruri; Daniel Diamond; Prakash Gorroochurn; Jeffrey M Liebmann; George A Cioffi; Lisa A Hark

Invest. Ophthalmol. Vis. Sci.. 2022; 63(7):3372 – A0159.

ARVO Annual Meeting Abstract June 2022

Topical glaucoma therapy is associated with alterations of the ocular surface microbiome

Chih-Chiun Jamie Chang; Karina Somohano; Christine Zemsky; Anne-Catrin Uhlemann; Jeffrey M Liebmann; George A Cioffi; Lama A Al-Aswad; Susan Lynch; Bryan Winn

Invest. Ophthalmol. Vis. Sci.. 2022; 63(7):4272.

ARVO Annual Meeting Abstract June 2022

Comparison of Global and Hemifield Rates of Visual Field (VF) Progression in Glaucoma

Johnny Xiang Li; Carlos G DeMoraes; Noga Harizman; Ari Leshno; Qing Wang; George A Cioffi; Jeffrey M Liebmann

Invest. Ophthalmol. Vis. Sci.. 2022; 63(7):1274 – A0414.

ARVO Annual Meeting Abstract June 2022

Manhattan Vision Screening and Follow-up Study: Ocular Pathology in Telemedicine Images

Rabia Karani; Jason D Horowitz; Weijie Violet Lin; Sitara Hirji; Ives A. Valenzuela; Stefania Maruri; David J. Doobin; Tarun Sharma; Daniel Diamond; Prakash Gorroochurn; Lisa Park; Qing Wang; Noga Harizman; Jeffrey M Liebmann; George A Cioffi; Lisa A Hark

Invest. Ophthalmol. Vis. Sci.. 2022; 63(7):1403 – A0099.

1 2 3 4

Next 20 Results »

NARROW

Content Type

Journal

Article Type

Topics

Tags

Specify Date Range

A Randomized, Sham Controlled, Masked Phase II Study for Safety of Intravitreal Implantation of NT-501 Encapsulated Cell Therapy for the Treatment of Glaucoma: Adverse Events and Structural Outcomes

Can modifiable behavioral factors be identified to increase activation in patients with glaucoma?

Racial and ethnic differences in baseline glaucoma disease severity

OCT metrics for the macular region are more sensitive for detecting glaucomatous progression than OCT circumpapillary metrics

Perimetric testing patterns focusing on the central visual field region can be more sensitive to glaucomatous progression than more peripheral patterns

Use of Topographical Structure–Function Agreement For Glaucoma Screening

Eyes with particular patterns of retinal ganglion cell damage at baseline are more likely to show glaucomatous progression

A combination of OCT metrics can detect glaucoma progression sooner than a VF benchmark criterion

Detecting Established Glaucoma Using OCT Alone: Utilizing an OCT Reading Center in a Real-World Clinical Setting

A Model of Progression to Help Identify Macular Damage Due to Glaucoma

An evaluation of OCT and visual field measures as endpoints of glaucoma progression

Focal OCT defects are predictors for future glaucoma progression in the same region

24-2 Visual Field Progression Rates Better Correlate with GCL than RNFL Rate of Change in Glaucoma

Manhattan Vision Screening and Follow-up Study (NYC-SIGHT) Cluster-Randomized Clinical Trial: Subanalysis of Telemedicine Retinal Findings

Topical Glaucoma Therapy Is Associated With Alterations of the Ocular Surface Microbiome

Evaluation of a Deep Learning Model on a Real-World Clinical Glaucoma Dataset

Manhattan Vision Screening and Follow-up Study: Epidemiologic characteristics of individuals referred to ophthalmology

Topical glaucoma therapy is associated with alterations of the ocular surface microbiome

Comparison of Global and Hemifield Rates of Visual Field (VF) Progression in Glaucoma

Manhattan Vision Screening and Follow-up Study: Ocular Pathology in Telemedicine Images

To View More...

You must be signed into an individual account to use this feature.